FDA Updates Drug Safety For Antiplatelet Medicine
The U.S. Food and Drug Administration (FDA) announced on Nov. 6 that long-term use of Plavix (clopidogrel) does not change the overall risk of death in cardiovascular disease patients. The determination was based on a meta-analysis of long-term trial results, including the DAPT Trial.
According to the Agency, “the results indicate that long-term (12 months or longer) dual antiplatelet therapy with clopidogrel and aspirin do not appear to change the overall risk of death when compared to short-term (6 months or less) clopidogrel and aspirin, or aspirin alone.”
< Back to Listings